Hypera Sa S/Adr

Good morning, ladies and gentlemen, and welcome to Ipera Pharma's conference call, where we will discuss our earnings for 2022. We have with us Mr. Breno Oliveira, CEO, and Mr. Adomario Couto, IRO. We'd like to inform you that this event is being recorded. You may access a recording of it in the company's investor relations website, epera.com.er. We'd like to inform you that all participants will be in listen-only mode during the company's presentation. After that, we will begin the questions and answers session when further instructions will be given. Before we continue, we'd like to underscore that some of the information in this conference call may refer to projections or statements on future expectations. This information is subject to known and unknown risks and uncertainties that may make them not come to pass or to be substantially different from what was expected. Now, we'd like to give the floor to Mr. the company's presentation. Mr. Brito, over to you. Good morning, everyone. Welcome to our earnings call for 2022 and for the fourth quarter of 2022. Last year was a very special one for Ipera. We reached all the guidances that we had published for the year. We grew our market share in retail. We advanced our strategy for the institutional market. We concluded the acquisition of the Sanofi brands, and we launched several new products across all of our business units. I'm going to start this presentation discussing our growth on slide three. Our sellout growth was 12% this year, a record for the company. It was 2.5 percentage points above market average growth in 2022. Our sellout grew organically above market rates for the second year in a row. And this time, it happened across all of our business units. This is a result of the initiatives that we used to boost our sustainable growth, especially increasing the pace of launches in the last few years, expanding our production capacity, and especially investing in our leading brands. It was a year of record marketing investments, which are essential to strengthen our irreplaceable portfolio of leading brands and boosting the growth of our new launches. Our advance in the institutional market this year was also a highlight, as I'll mention in slide four. The institutional market contributed with over 380 million Brazilian reals to our net income in 2022 versus 145.6 million in 2021. This is due to the initiatives implemented by the new business unit created in 2021, which contributed to a 70% growth in our existing product portfolio in this segment, and also an additional income from a non-recurring cell of the immunoglobulin, representing about 130 million BRL last year. We also concluded the investments in our new injectable plant in 2022 in Annapolis, and we continued creating our new innovation center, our new pilot plant, and an oncological product plant to support our growth in the institutional market, which should be concluded still this year. We currently have a pipeline of 87 new molecules to be launched in the next few years in the institutional segment. And in 2022, we have already launched our first antibiotics, cefepime, cefuroxime, and Baxulfatrin. a record organic growth in retail sellout, in addition to the contribution from the Sanofi brands acquired in the first quarter of 2022. And our sales going up in the institutional market allowed us to have a net income of 27% growth in 2022. We also reached record EBITDA levels for our continued operation and the highest cash generation in 2022. our history, and Adomario will mention this soon. We had significant operational and financial advances this year, and we maintained our commitment to sustainable growth, to paying our shareholders, and to maintaining our stakeholders' well-being. We speak about innovation on slide 5. We launched over 90 products this year, and we made record investments in research and development. totaling about 520 million euro in prescription products. We are working in new markets such as contraceptives and cannabidiol. We were the first to go into the Epixaban market after the patent was broken, and we launched ONDIF for the treatment and prevention of nausea. In consumer health, our highlights were Engov Up, a new extension of the Engov brand line, and further line extensions for Myrtillate, Epoclare, Buscopana, and Neosaldina. In biosimilars and generics, the company advanced a strategy to increase its coverage in generic molecules. Ladies and gentlemen, please hold while we reconnect.

ladies and gentlemen please hold while we reconnect

Hi, everyone. I'm not sure if you can hear me.